ReviewTherapeutic advances in gastroenterology2017
The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Review in Therapeutic advances in gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- GERD and Upper Aerodigestive Tract Cancer Risk: A Systematic Review and Meta-Analysis.The Laryngoscope · 2026Pooled it
- Efficacy of Shugan Hewei formula combined with rabeprazole in refractory gastroesophageal reflux disease: randomized, double-blind, placebo-controlled trial.European journal of medical research · 2024Trial
- Efficacy of a Food Supplement ContainingNutrients · 2024Trial
- Article
- Pepsin-driven corrosion of orthodontic titanium alloys in candidiasis-simulated saliva: electrochemical and statistical insights.Scientific reports · 2026Article
- Childhood gastroesophageal reflux disease: A comprehensive review of disease, diagnosis, and therapeutic management.World journal of clinical pediatrics · 2025Review
- Evaluation of the Susceptibility of Bangladeshi University Students to Gastroesophageal Reflux Disease (GERD) and Its Associated Factors: A Cross-Sectional Study.Health science reports · 2025Article
- Article
- Evaluation of the impact of oesophageal reflux disease on muscle fatigue.European journal of translational myology · 2024Article
- Article
- Epidemiology, Causes, and Management of Gastro-esophageal Reflux Disease: A Systematic Review.Cureus · 2023Review
- Development of Novel Balloon-Integrated Optical Catheter for Endoscopic and Circumferential Laser Application.Annals of biomedical engineering · 2023Article
- Revision paraesophageal hernia repair outcomes in patients with typical and atypical reflux.Surgical endoscopy · 2023Article
- Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review.International journal of environmental research and public health · 2021Review
- Refractory Gastroesophageal Reflux Disease: A Management Update.Frontiers in medicine · 2021Review
- Comparing Efficacy and Safety of Empirical vs. Guided Therapy for Non-cardiac Chest Pain: A Pragmatic Randomized Trial.Frontiers in medicine · 2021Article
- Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application.Journal of pharmaceutical analysis · 2020Article
- Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.Journal of neurogastroenterology and motility · 2020Article
- Potent Acid Suppression with PPIs and P-CABs: What's New?Current treatment options in gastroenterology · 2018Review
- Refractory Heartburn: A Challenging Problem in Clinical Practice.Digestive diseases and sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexlansoprazole modified-release (MR) is the R-enantiomer of lansoprazole and is currently the only proton-pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation. Overall, dexlansoprazole MR demonstrates a similar safety and side-effect profile as lansoprazole. Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). Recent studies have also demonstrated that dexlansoprazole MR is highly effective in improving nocturnal heartburn, gastroesophageal reflux disease (GERD) related sleep disturbances and bothersome regurgitation. Dexlansoprazole MR is well tolerated and can be taken without regard to food.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.